A novel cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy:mavacamten
Hypertrophic cardiomyopathy(HCM)is a common type of cardiomyopathy,with approximately two-thirds of cases presenting as obstructive hypertrophic cardiomyopathy(oHCM).Mavacamten,the first heart-specific myosin inhibitor,was approved by the U.S.FDA in April 2022 for the treatment of adult patients with symptomatic oHCM and heart function classified as NYHA class Ⅱ to Ⅲ.Mavacamten reversibly inhibits actin-myosin binding,reduces the cross-bridge cycle,and decreases myocardial hypercontractility.Recent phase Ⅱ and phase Ⅲ clinical trials have demonstrated that Mavacamten reduces left ventricular outflow tract pressure and improves both cardiac function and exercise tolerance.The mechanism of action,clinical value and safety profile of Mavacamten are reviewed.
NETL
NSTL
万方数据
